| Literature DB >> 34330194 |
Martin Pehrsson1,2, Joachim Høg Mortensen2, Tina Manon-Jensen2, Anne-Christine Bay-Jensen1, Morten Asser Karsdal2, Michael Jonathan Davies1.
Abstract
Introduction: Enzymatic cross-linking of the collagens within the extracellular matrix (ECM) catalyzed by enzymes such as lysyl oxidase (LOX) and lysyl oxidase like-enzymes 1-4 (LOXL), transglutaminase 2 (TG2), and peroxidasin (PXDN) contribute to fibrosis progression through extensive collagen cross-linking. Studies in recent years have begun elucidating the important role of collagen cross-linking in perpetuating progression of organ fibrosis independently of inflammation through an increasingly stiff and noncompliant ECM. Therefore, collagen cross-linking and the cross-linking enzymes have become new targets in anti-fibrotic therapy as well as targets of novel biomarkers to properly assess resolution of the fibrotic ECM.Areas covered: The enzymatic actions of enzymes catalyzing collagen cross-linking and their relevance in organ fibrosis. Potential biomarkers specifically quantifying proteolytic fragments of collagen cross-linking is discussed based on Pubmed search done in November 2020 as well as the authors knowledge.Expert opinion: Current methods for the assessment of fibrosis involve the use of invasive and/or cumbersome and expensive methods such as tissue biopsies. Thus, an unmet need exists for the development and validation of minimally invasive biomarkers of proteolytic fragments of cross-linked collagens. These biomarkers may aid in the development and proper assessment of fibrosis resolution in coming years.Entities:
Keywords: Collagen cross-linking; cross-linking biomarkers; fibrosis resolution; lysyl oxidase; organ fibrosis; peroxidasin; transglutaminse 2
Mesh:
Substances:
Year: 2021 PMID: 34330194 DOI: 10.1080/14737159.2021.1962711
Source DB: PubMed Journal: Expert Rev Mol Diagn ISSN: 1473-7159 Impact factor: 5.225